Related Experiment Video
Updated: May 3, 2026

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
Published on: May 17, 2024
Myogenic tumors in nevoid Basal cell carcinoma syndrome
Simone Hettmer1, Lisa A Teot, Harry Kozakewich
1*Department of Pediatric Oncology, Dana-Farber Cancer Institute †Division of Pediatric Hematology/Oncology, Boston Children's Hospital ¶Department of Pathology, Boston Children's Hospital ‡Howard Hughes Medical Institute §Department of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, Harvard University ∥Joslin Diabetes Center #Department of Pathology, Brigham and Women's Hospital, Boston, MA.
Abstract:
In mice, activated Hedgehog (Hh) signaling induces tumors with myogenic differentiation. In humans, hyperactive Hh signaling due to germline PATCHED1 (PTCH1) mutations has been linked to nevoid basal cell carcinoma syndrome (NBCCS). We report an embryonal rhabdomyosarcoma in a 16-month-old girl with NBCCS and review the literature on myogenic neoplasms in NBCCS, including 8 fetal rhabdomyomas and 3 rhabdomyosarcomas. Of note, 3 population studies, including 255 individuals with NBCCS aged 4 months to 87 years, did not identify any myogenic tumors. Thus, myogenic tumors in NBCCS are rare and include both rhabdomyosarcomas and fetal rhabdomyomas.
More Related Videos
09:33Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
Published on: August 25, 2023
09:37Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
Published on: August 25, 2021
Related Concept Videos
Abnormal Proliferation
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Myasthenia Gravis ll: Pathophysiology